New York (PRWEB) November 05, 2012
One of the most frequently asked questions that parents-to-be have when they are deciding whether or not to bank their baby’s cord blood is how likely it is that their baby will benefit from the banked cord blood. Stem cells are already in use in medical therapies for more than 80 diseases and conditions. In addition, stem cell therapy is the subject of hundreds of clinical trials and hundreds of millions of dollars of research in the United States and around the world, making it likely that in the future the uses will continue to be expanded and improved for children and adults.
One of the most exciting studies currently in progress is being led by Dr. Joanne Kurtzberg, Director of the Pediatric Bone Marrow and Transplant Program at Duke University. The study is examining whether an infusion of a child’s own cord blood cells can lessen symptoms of cerebral palsy. Cerebral palsy is a non-genetic neurological disorder. It is caused by damage to one or more areas of the brain, usually occurring during fetal development or infancy. The Brain Injury Association of America estimates that cerebral palsy occurs in about 1 in 300 children up to the age of 10.
In a recent interview about the study, Dr. Kurtzberg was asked about the benefit of using the patient’s own cord blood rather than cord blood from a donor. In response she said, “When you use your own cord blood there’s no risk that the cord blood cells will react against you, when you use donor cord blood there is a risk that the donor cells will react against the patient, that’s called graft versus host disease and that’s a major limitation and complication of a transplant with a donor cell.” The study that Dr. Kutzberg is leading, which has shown encouraging results thus far, is anticipated to be complete in 2013.
Americord Registry believes that privately banking stem cells is a once in a lifetime opportunity for parents-to-be to expand their baby’s options for medical treatments such as those being pursued by Dr. Kurtzberg and other scientists worldwide. In addition to offering fees that are dramatically lower than those of competitors, Americord also offers a budget-friendly payment plan option enabling parents-to-be to pay the full amount over 12 monthly installments. Americord’s fee covers the collection of stem cells, transport of the cells via medical courier, and 20 years of storage in a state-of-the-art facility. For further information, including a comparison of the fees of leading cord blood banks, visit Americord online at http://cordadvantage.com or call 866-503-6005.
About Americord Registry
Americord Registry is a leader in the advancement of cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratories are CLIA Certified, accredited by the AABB and comply with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry's website at http://www.cordadvantage.com for more information. You may also find Americord Registry on Facebook and follow the company on Twitter.